1,702
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations

, , , , &
Pages 1155-1162 | Received 30 Mar 2017, Accepted 15 Jul 2017, Published online: 16 Aug 2017

Figures & data

Figure 1. An example of choice task questions in discrete choice experiment survey.

Figure 1. An example of choice task questions in discrete choice experiment survey.

Table 1. Attributes and attribute levels in discrete choice experiment.

Table 2. Medical cost reduction for prostate cancer patients with injections of leuprorelin acetate.

Table 3. Intangible costs for one injection by discrete choice experiment.

Table 4. Intangible costs saved for having one less injection in prostate cancer patients with injections of leuprorelin acetate. Note that intangible costs saved for having one less injection were calculated by the results of discrete choice experiment on respondents without prostate cancer.

Table 5. Sensitivity analysis of intangible costs saved for having one less injection in prostate cancer patients with injections of leuprorelin acetate.

Table 6. Total costs reduction for having one less injection in prostate cancer patients with injections of leuprorelin acetate.

Supplemental material

Supplemental table 1

Download JPEG Image (385.3 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.